Sino Biopharmaceutical (FRA:SMZ1) Interest Expense : €-64 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sino Biopharmaceutical's interest expense for the six months ended in Dec. 2023 was € -25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-64 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sino Biopharmaceutical's Operating Income for the six months ended in Dec. 2023 was € 308 Mil. Sino Biopharmaceutical's Interest Expense for the six months ended in Dec. 2023 was € -25 Mil. Sino Biopharmaceutical's Interest Coverage for the quarter that ended in Dec. 2023 was 12.56. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sino Biopharmaceutical Interest Expense Historical Data

The historical data trend for Sino Biopharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Interest Expense Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-29.51

-40.65

-42.88

-58.16

-63.60

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-22.43	-23.92	-35.24	-39.20	-24.54

Sino Biopharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-64 Mil.

Sino Biopharmaceutical (FRA:SMZ1) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sino Biopharmaceutical's Interest Expense for the six months ended in Dec. 2023 was €-25 Mil. Its Operating Income for the six months ended in Dec. 2023 was €308 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was €176 Mil.

Sino Biopharmaceutical's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	308.174	/	-24.543
	=	12.56

The higher the ratio, the stronger the company's financial strength is.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines